SBIR/STTR Research Award

Expansion of an efficient drug repurposing platform for rare genetic diseases.

Award identifier 0bb8958ac4c4617321a57d18b85618da3e249430698a5de4b58e8f61a75451c4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,459,171

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Recursion Pharmaceuticals, LLC
Proposal award date
2015-03-01
Contract end date
2018-02-28
UEI
K19FFWF23DK3
Solicitation number
PAR14-088
Topic code
300

Research abstract

DESCRIPTION provided by applicant There are thousands of rare genetic diseases that have no approved treatment Recursion Pharmaceuticals has developed a drug discovery platform that seeks to re purpose known drugs for the treatment of such diseases The platform consists of high content immunofluorescent image analysis and transcellular resistance measurements These measurements evaluated using machine learning algorithms to identify relevant and on target changes induced by both RNAi and various chemicals These assays can be simultaneously performed on thousands of rare genetic disease models In this grant we specifically propose to Model genetic diseases in multiple human cell types using RNAi technology Identify and prioritize of these disease models with the most compelling phenotypic changes according to multi parametric quantification Utilize these disease models as the basis of chemical suppressor screens of thousands of known drug candidates Validate the best drug disease combinations using an orthogonal genetic manipulation technique in human cells Study the best five to ten validated drug disease combinations in relevant animal models The proposed study would have significant societal and commercial implications PUBLIC HEALTH RELEVANCE There are thousands of rare genetic diseases that together affect millions of Americans We will use chemical suppressor screens of known drugs based on structural and functional changes in cellular disease models to identify potential therapeutics for treatment of these diseases

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2015–2018). Reported award amounts total $3,515,236. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.